Drug Database
SU

sumatriptan succinate (Zelrix / NP101 / Zecuity)

✓ Approved

Nupathe Inc. · HTR1D · Small Molecule

What is sumatriptan succinate?

sumatriptan succinate is a small molecule developed by Nupathe Inc.. It is approved for therapeutic indications via topical or transdermal.

Drug Profile

Brand NamesZelrix, NP101, Zecuity
CompanyNupathe Inc.
Drug ClassSmall Molecule
Molecular TargetHTR1D
RouteTopical, Transdermal
StatusApproved

Mechanism of Action

Molecular Targets

sumatriptan succinate acts on 1 molecular target:

HTR1D5-hydroxytryptamine receptor 1D (HTR1DA, HT1DA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

sumatriptan succinate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersMigraine✓ Approved

Related Research Articles

PubMedJournal of agricultural and food chemistry2026-07-17

Coumarin Hydrazone Derivatives as Potent Succinate Dehydrogenase Inhibitors and Effective Antifungal Agents against Rhizoctonia solani.

Chen Wang W, Fu Lixiang L, Wang Chunyan C, Mu Yalin Y et al.

Succinate dehydrogenase inhibitors (SDHIs) are widely used worldwide for their broad-spectrum antifungal activity. Structural optimization of natural products offers a viable route to novel SDHI skeletons. Herein, a series of coumarin hydrazone derivatives were designed and synthesized by a scaffold splicing strategy. Compound 3p showed 100% antifungal activity against Rhizoctonia solani at 50 μg/mL, with an EC50 of 1.16 μg/mL. On rice leaves, 3p achieved 98.4% preventive efficacy against R. solani, outperforming Boscalid (69.6%) at the same concentration. Furthermore, it caused hyphal distortion and mitochondrial damage, similar to boscalid. Enzymatic assays confirmed 3p as an SDHI with an IC50 of 8.69 μM, and molecular docking indicated stable binding within the SDH active site. ATP analysis revealed intracellular levels were reduced to 72% in 3p-treated mycelia compared to controls. Therefore, compound 3p is a promising leader for developing novel SDH inhibitors.

PubMedbioRxiv : the preprint server for biology2026-07-17

Advanced Open-source Experimental-Design Tools for Microplate-Based Assays with Acoustic Liquid Handling.

Kattunga Varunya M VM, Wrobel Steven A SA, Lerner Chad A CA, Derycz Victor M VM et al.

Acoustic droplet ejection (ADE) enables nanoliter-scale liquid handling for complex microplate assays, yet translating experimental designs into validated, instrument-ready instructions remains a bottleneck. We present PickliPy, an open-source framework that converts spreadsheet-based assay designs into validated ADE picklists. PickliPy.Assay supports combinatorial, dose-response, and multi-addition time-course dispensing, while PickliPy.Screen extends to high-throughput workflows, including library reformatting and shortlisting. Across diverse biological contexts, the framework generated reproducible, assay-ready plates and standardized execution in human cohort studies. Acoustic pre-dispensing deepened bioenergetic phenotyping of isolated human skeletal muscle mitochondria, capturing substrate switching, and sharpened dose-response precision in human pancreatic β-cells, revealing an age-associated change in succinate dehydrogenase kinetics. We benchmarked a wash-free, live-cell screen of mitochondrial function and morphology, in which deep-learning image analysis widened the assay window and ADE enabled integrative dose-response co-response analysis. Together, these tools make complex ADE experiments easier to design, reproduce, and scale from single benches to screening campaigns.

PubMedCureus2026-07-17

Silent Phaeochromocytoma in a Young Normotensive Woman.

Badiani Ashakumari A, Siew Stephanie S, Al-Ansari Mustafa M

Phaeochromocytomas typically present with episodic palpitations, sweating and headaches, often with paroxysmal hypertension. In contrast, a smaller proportion are detected incidentally and may be normotensive, creating diagnostic challenges. We present the case of a 28-year-old British Indian woman who was incidentally found to have a right adrenal mass on computed tomography (CT) performed following an occupational abdominal injury. She was normotensive at the time and did not describe symptoms of classical catecholamine excess. However, she reported intermittent anxiety-like symptoms, which she attributed to work-related stress. Contrast-enhanced CT of the abdomen and pelvis revealed a 4cm right adrenal lesion with high attenuation of ~90 Hounsfield units (HU) and a heterogeneous appearance, raising suspicion of a non-adenomatous adrenal mass. Biochemical analysis demonstrated significantly raised plasma metanephrines on two separate occasions, consistent with phaeochromocytoma. Following multidisciplinary team (MDT) discussion, she was commenced on phenoxybenzamine and subsequently underwent an elective laparoscopic right adrenalectomy. Histology confirmed a completely excised phaeochromocytoma with low-risk features (Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) 2; Ki-67 <2%) and retained succinate dehydrogenase subunit B (SDHB) staining. Post-operatively, she remained normotensive, and follow-up plasma metanephrines were normal, with no evidence of residual disease. This case illustrates the diagnostic difficulties that can arise in normotensive, minimally symptomatic patients, and highlights the importance of systematic MDT evaluation of adrenal incidentalomas and cautious peri-operative planning, even in "silent" disease.

PubMedInternational immunopharmacology2026-07-17

Itaconic acid alleviates acute hepatitis by reprogramming NK cell metabolism with mitochondrial dysfunction.

Sun Ying Y, Duan Mingyue M, Zhang Xi X, Liu Xiaoguai X et al.

Immunometabolism provides critical insights into the pathogenesis and treatment of inflammatory diseases. Itaconic acid (ITA), a key immunomodulatory metabolite derived from the tricarboxylic acid cycle, has been extensively characterized in macrophages; however, its direct effects on NK cells and NK cell-mediated liver pathology remain poorly defined. Using SCENITH and Seahorse analyses, we assessed ITA's impact on NK cell metabolism via multi-omics, and investigated its underlying mechanisms. The therapeutic potential was then evaluated in a mouse model of poly (I:C)-induced liver injury. We show that ITA reprograms NK cell metabolism to suppress their proliferation and killing capacity, simultaneously suppressing oxidative phosphorylation while inducing a compensatory glycolytic shift. Multi-omics integration revealed that this metabolic shift corresponds with the upregulation of glycolytic gene networks and significant mitochondrial impairment, mechanistically linked to the inhibition of succinate dehydrogenase (SDH) activity and the downregulation of the NRF1/TFAM mitochondrial biogenesis pathway. ITA also damages mitochondria and impairs autophagic activity, resulting in accumulation of dysfunctional mitochondria in NK cells. All these alterations lead to profound suppression of NK cell proliferation and cytotoxic function. Administration of ITA in mice with poly (I:C) -induced liver injury substantially attenuated hepatic damage and suppressed over-inflammation in the liver. This protective effect was associated with inhibited hepatic infiltration and function of both NK and T cells. Our findings extend the understanding of the immune regulation and metabolic reprogramming of ITA to NK cells, showing that ITA inhibits SDH activity to down-regulate mitochondrial biogenesis through NRF1/TFAM in NK cells with consequent limitation of cytotoxic function, suggesting the further therapeutic potential of ITA application in NK cells-mediated liver pathologies.

PubMedFrontiers in microbiology2026-07-17

Engineered microbes to enable a circular economy for biodegradable plastics.

Madushanka Dushmantha D, Beard Cole C, Kolitha Bhagya S BS, Dissanayake Lakshika L et al.

Plastic pollution resulting from the continued dominance of fossil-derived polymers is a major global environmental challenge. Although biodegradable plastics, such as polylactic acid (PLA), polyhydroxyalkanoates (PHAs), polybutylene succinate (PBS), polybutylene adipate terephthalate (PBAT), and related materials, are increasingly being deployed as alternatives, their environmental performance is frequently constrained by infrastructure gaps, uncontrolled carbon loss, and incomplete degradation under realistic conditions. Therefore, biodegradability alone does not guarantee circularity of the material. To address this, intentional rerouting of plastics and their monomers into upcycling streams offers a widely applicable solution. This review advances the circular bioeconomy framework built on engineered depolymerization and metabolic bio-funneling of biodegradable and selected synthetic plastics. We present recent progress in enzyme-mediated polyester breakdown, emphasizing hydrolases and oxidoreductases, the kinetic and structural determinants of activity, and protein engineering strategies that broaden substrate scope and enhance operational stability. We then organize bio-upcycling strategies according to key metabolic entry nodes: pyruvate, acetyl-CoA/β-oxidation, and aromatic/dicarboxylate pathways, to demonstrate how plastic-derived monomers can be systematically redirected toward platform chemicals, fuels, specialty monomers, and next-generation biopolymers through pathway rewiring, flux control, and redox balance. In addition to biological conversion, we evaluate chemo-biological hybrid systems and integrated techno-economic and life cycle considerations, including process efficiency, enzyme cost, toxicity mitigation, and infrastructure compatibility. We further highlight emerging tools, such as systems biology, adaptive laboratory evolution, synthetic consortia design, and machine-learning-guided protein optimization, which accelerate the design-build-test-learn cycle for scalable microbial platforms for plastic upcycling. Collectively, this study reframes biodegradable plastics not as materials designed merely to disappear but as programmable carbon reservoirs that can be captured, upgraded, and reintegrated into biomanufacturing value chains. Actively closing the loop through engineered bio-upcycling, rather than relying on passive environmental degradation, offers a practical pathway to align plastic utility with environmental sustainability and achieve a truly circular bioeconomy.

PubMedEuropean journal of clinical pharmacology2026-07-16

Unveiling the sumatriptan dose-relief relationship.

Rigaut Clément C, Haut Benoit B, Lambert Pierre P, Goole Jonathan J

This article aims to correlate the pharmacokinetic parameters of sumatriptan to the percentage of patients experiencing relief after two hours. Using data from the literature, a two-compartment pharmacokinetic model is developed to compute the concentration of sumatriptan in the brain across various routes of administration and doses. This concentration is then correlated to its clinical effect. The maximum concentration of sumatriptan in the brain correlates linearly with the percentage of patients experiencing pain relief after two hours. Based on the evolution over time of the brain concentration, the action time can also be predicted for different route-dose combinations. The present correlation provides a relationship between the dose of sumatriptan and its effect for multiple routes of administration. The approach developed in this work could be adapted to other molecules to explore their dose-response relationships.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about sumatriptan succinate